NVIDIA
NVDA
Tesla
TSLA
Taiwan Semiconductor
TSM
4
Palantir
PLTR
5
Intel
INTC
US Stock MarketDetailed Quotes
ADVM Adverum Biotechnologies
- 4.1600
- -0.5500-11.68%
Close Mar 3 16:00 ET
86.54MMarket Cap-0.70P/E (TTM)
5.1400High4.1500Low267.77KVolume4.6900Open4.7100Pre Close1.22MTurnover2.10%Turnover RatioLossP/E (Static)20.80MShares19.100052wk High0.60P/B52.93MFloat Cap3.520052wk Low--Dividend TTM12.72MShs Float624.8000Historical High--Div YieldTTM21.02%Amplitude3.5200Historical Low4.5440Avg Price1Lot Size
Adverum Biotechnologies Stock Forum
Sign in to post a comment
$Adverum Biotechnologies (ADVM.US)$ Reuters· 2 mins ago
Adverum Biotechnologies Initiates Artemis Phase 3 Study Evaluating Ixo-Vec for Wet AMD
Adverum Biotechnologies Initiates Artemis Phase 3 Study Evaluating Ixo-Vec for Wet AMD
2
2
$Adverum Biotechnologies (ADVM.US)$
Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD
Monday, 3rd March at 4:01 pm
•Ixo-vec is a potential best-in-class one-time gene therapy designed to deliver long-term efficacy, reduce the burden of frequent anti-VEGF and improve vision outcomes for patients with wet AMD
•ARTEMIS is the first-ever initiation of a registrational intravitreal gene therapy trial in patients with wet AMD
•Non-inferiority study to eval...
Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD
Monday, 3rd March at 4:01 pm
•Ixo-vec is a potential best-in-class one-time gene therapy designed to deliver long-term efficacy, reduce the burden of frequent anti-VEGF and improve vision outcomes for patients with wet AMD
•ARTEMIS is the first-ever initiation of a registrational intravitreal gene therapy trial in patients with wet AMD
•Non-inferiority study to eval...
2
NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; F...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; F...
77
6
$Scorpius Holdings (SCPX.US)$ $Perspective Therapeutics (CATX.US)$ $Turbo Energy (TURB.US)$ $Adverum Biotechnologies (ADVM.US)$ $NFT Ltd (MI.US)$ $Xylo Technologies (XYLO.US)$ $Lipocine (LPCN.US)$ $Massimo (MAMO.US)$ $China Jo-Jo Drugstores (CJJD.US)$ $Edesa Biotech (EDSA.US)$ $Atara Biotherapeutics (ATRA.US)$ $Eterna Therapeutics (ERNA.US)$ $DDC Enterprise (DDC.US)$
📊⚡️📊
📊⚡️📊
$Adverum Biotechnologies (ADVM.US)$ Reuters· just
Adverum Biotechnologies Announces FDA Regenerative Medicine Advanced Therapy (Rmat) Designation Granted for Ixo-Vec for the Treatment of Wet AMD
Adverum Biotechnologies Announces FDA Regenerative Medicine Advanced Therapy (Rmat) Designation Granted for Ixo-Vec for the Treatment of Wet AMD
1
$Adverum Biotechnologies (ADVM.US)$
Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting
Adverum Biotechnologies (Nasdaq: ADVM) presented positive 26-week interim results from the LUNA Phase 2 trial of Ixo-vec for wet AMD at the 2024 ASRS Annual Meeting. Key findings include:
1. The 6E10 dose with local prophylaxis was selected for Phase 3 trials.
2. 76% of 6E10 patients were injection-fr...
Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting
Adverum Biotechnologies (Nasdaq: ADVM) presented positive 26-week interim results from the LUNA Phase 2 trial of Ixo-vec for wet AMD at the 2024 ASRS Annual Meeting. Key findings include:
1. The 6E10 dose with local prophylaxis was selected for Phase 3 trials.
2. 76% of 6E10 patients were injection-fr...
2
$Adverum Biotechnologies (ADVM.US)$
NEWS
Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting
NEWS
Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting
$Adverum Biotechnologies (ADVM.US)$ Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD
4 MINUTES AGO, 7:00 AM EST
VIA GLOBENEWSWIRE
– Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and maintenance of both visual acuity and anatomic endpoints –
– Preliminary safety data support a favorable benefit-risk pr...
4 MINUTES AGO, 7:00 AM EST
VIA GLOBENEWSWIRE
– Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and maintenance of both visual acuity and anatomic endpoints –
– Preliminary safety data support a favorable benefit-risk pr...
1
2
No comment yet
ColdJoke : it looks they really want to go to moon
Trytosaveabit OP ColdJoke : Just bounced off 52Wk low Wednesday! Needs volume. Volume could give it a decent price increase. GL